Monday, July 19, 2021 5:05:40 PM
The decision to not go forward with Phase 3 because of costs and a waning COVID pandemic seems almost logical but to say data was not strong and just DROP Ifenprodil until after IPF/CC data???
Another stock is running well on weaker data for IL1 and IL-6, but they followed patients to 60 days to get something to present. (Mostly fluff, IMO) 195 patients and AGN treated 165.
Yep. screwed us hard with no Real explanation - no comment on what went right - no direction - and putting a snuffer on Ifenprodil by saying weak data??? WTF???
I have avoided bashing, butt, WTF? Inept? Stupid?...GLTA...
https://www.globenewswire.com/en/news-release/2021/05/12/2228023/0/en/Algernon-Pharmaceuticals-Announces-Ifenprodil-Reduced-Interleukin-6-in-Phase-2b-3-COVID-Study.html
https://www.globenewswire.com/en/news-release/2021/03/31/2202350/0/en/Algernon-Pharmaceuticals-Announces-Topline-Data-From-its-Phase-2b-3-COVID-19-Trial-of-Ifenprodil.html
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM